Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Idera Presents IMO-3100 for Arthritis

By Drug Discovery Trends Editor | July 1, 2011

Idera Pharmaceuticals, Inc. announced IMO-3100 mechanism of action data in a preclinical model of arthritis.

In this study, the improvements in disease-related parameters resulting from IMO-3100 treatment were associated with suppression of interleukin 6 and complement C3 and with induction of interleukin 10.

“Treatment with IMO-3100 showed significant reduction in arthritis symptoms compared to placebo in this study,” comments Nicola La Monica, PhD, vice president of biology, Idera Pharmaceuticals.

“Furthermore, in agreement with the intended mechanism of action, the therapeutic effect exerted by IMO-3100 was associated with decreased expression of the inflammatory proteins IL-6 and IL-1?, and increased expression of the anti-inflammatory protein IL-10.”

 “In Phase 1 studies in healthy subjects, IMO-3100 was well tolerated and suppressed TLR7- and TLR9-mediated induction of cytokines including TNF-?, IFN-?, IP-10 and IL-6, consistent with the intended mechanism of action.  We plan to initiate a Phase 2 clinical trial of IMO-3100 in a selected autoimmune indication by the end of this year,” says Sudhir Agrawal, D.Phil., chairman and chief executive officer of Idera.

IMO-3100 was evaluated in a preclinical model in which arthritis was induced by injection of collagen antibodies into BALB/c mice.  Treatment with IMO-3100 led to dose-dependent suppression of disease development as measured by standard arthritis scoring criteria and associated histopathology. IMO-3100 treatment was associated with induction of IL-10, and increased serum levels of IL-10 were correlated with improvement in clinical scores. IMO-3100 suppressed serum levels of complement C3 and tissue deposition of complement C3 and C5a, immune system proteins that play a role in the development of inflammation. Treatment with IMO-3100 was associated with reduced messenger RNA expression of IL-1? and IL-6 compared to placebo treatment.

Release Date: June 23, 2011
Source: Idera Pharmaceuticals 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE